Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Akari Therapeutics Plc AKTX

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:AKTX)

Fundamentals Snapshot (NDAQ:AKTX)

Current News (NDAQ:AKTX)

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

GlobeNewswire 4 days ago

Akari Therapeutics Announces $12.75 Million Registered Direct Offering

GlobeNewswire September 12, 2022

Akari Therapeutics Narrows Pipeline Focus

GlobeNewswire August 1, 2022

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

GlobeNewswire July 28, 2022

Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

GlobeNewswire July 20, 2022

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

GlobeNewswire July 7, 2022

Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies

GlobeNewswire June 13, 2022

Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting

GlobeNewswire May 19, 2022

Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress

GlobeNewswire May 16, 2022

Opinion & Analysis (NDAQ:AKTX)

No current opinion is available.

Bullboard Posts (NDAQ:AKTX)

RE:Rumour Mill Whispers..

http://investor.akaritx.com/static-files/50c90eba-430c-4e52-b500-9462bb00ada8
InsideTweeter - December 11, 2021

Rumour Mill Whispers..

Watch this..!!  Market cap $75M - Robust Pipeline - Acquisition value of similar companies in complement space with similar...
InsideTweeter - December 11, 2021

it's a buy today for me

at $4.25 per share,so glta.
coolfooldumbguy - April 23, 2019

it's a sell today for me

I am too busy day trading stocks right now,so glta but there is no time for me to post all of my buy & sells anymore for you guys.
coolfooldumbguy - March 14, 2019

RE:Been strong all day..............

YYEEEHHHAAA.............$ 11.20 high ......15 minutes to the close.!!!!!!!!!!!!!! SSSSSSAAAAAWWWWWEEEETTTT !!!!!!!!!!!!!!!!!!!!!!!!
Iseneschal - March 31, 2017

Been strong all day..............

This will break $11 before the close...........Monday gap up! JMHO
Iseneschal - March 31, 2017